Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696598 | 0.92 | GRM5 (0.46) | METAP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7382660 | 0.90 | METAP1 (0.42) | METAP1KDM4ENAMPTCYP17A1ATR | |
| SCHEMBL30450099 | 0.90 | METAP1 (0.42) | METAP1KDM4ENAMPTCYP17A1ATR | |
| SCHEMBL29919808 | 0.89 | METAP1 (0.45) | METAP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL69347 | 0.89 | METAP1 (0.45) | METAP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2693327 | 0.87 | METAP1 (0.43) | METAP1KDM4EALDH1A1NAMPTCYP17A1 | |
| SCHEMBL7419909 | 0.87 | METAP1 (0.39) | METAP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL27703346 | 0.85 | METAP1 (0.44) | METAP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7410155 | 0.85 | LMNA (0.39) | METAP1KDM4ECNR2 | |
| SCHEMBL8609349 | 0.84 | METAP1 (0.42) | METAP1KDM4ENAMPTCYP17A1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2452940-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | METAP1 4461/4885KDM4E 1059/4885ALDH1A1 3382/4885 |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | METAP1 4461/4885KDM4E 1059/4885ALDH1A1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.